



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAR 28 2003

TECH CENTER 1600/2000

Applicant : Kjell G.E. Bäckström et al. Art Unit : 1653  
Serial No. : 08/736,267 Examiner : D. Lukton  
Filed : October 24, 1996  
Title : THERAPEUTIC PREPARATION FOR INHALATION

Commissioner for Patents  
Washington, D.C. 20231

**TERMINAL DISCLAIMER UNDER 37 CFR §§3.73(b) AND 1.321(b)**

Pursuant to 37 CFR §3.73(b), ASTRAZENECA AB, a Swedish corporation, certifies that it is the assignee of the entire right, title, and interest in the above-captioned application by virtue of an assignment from the inventors of the above-captioned application to AB Astra. The assignment to AB Astra was recorded in the Patent and Trademark Office at Reel 7172, Frame 0512 on September 6, 1994. AstraZeneca AB is the present name of the corporation formerly known as AB Astra. A copy of the Certificate of Registration of the corporate name, AstraZeneca AB, was recorded on January 22, 2001, at Reel 011469, Frame No. 0958. A copy of the Certificate of Registration is attached hereto. Page 3 of the Certificate of Registration lists Aktiebolaget Astra (also known as AB Astra) and Astra Aktiebolag as previous company names of AstraZeneca AB.

The undersigned has reviewed all the documents in the chain of title of the above-captioned application, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

AstraZeneca AB also certifies that it is the successor of Astra Aktiebolag, which is the assignee of the entire right, title, and interest in U.S. Patent No. 6,436,902 (the '902 Patent), issued from USSN 09/383,590, by virtue of an assignment from the inventors to Astra Aktiebolag. A copy of that assignment was recorded in the Patent and Trademark Office at Reel 010408, Frame 0200 on November 22, 1999. The Certificate of Registration certifying the name change to AstraZeneca AB was recorded at Reel 011505, Frame 0723 on February 5, 2001.

03/27/2003 CVO111 0000033 08736267

02 FC:1814 110.00 OP  
03 FC:1814 110.00 OP  
04 FC:1814 110.00 OP

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on March 17, 2003 and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

05 FC:1814  
06 FC:1814  
07 FC:1814110.00 OP  
110.00 OP  
110.00 OPSignature  
Joanne D. Boyle  
Typed or Printed Name of Person Signing Certificate

The undersigned has reviewed all the documents in the chain of title of the '902 Patent, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

AstraZeneca AB also certifies that it is the successor of Astra Aktiebolag, which is the assignee of the entire right, title, and interest in U.S. Patent No. 5,747,445 (the '445 Patent), issued from USSN 08/583,205, by virtue of an assignment from the inventors thereof to Astra Aktiebolag. A copy of that assignment was recorded in the Patent and Trademark Office at Reel 8188, Frame 0576 on April 8, 1996.

The undersigned has reviewed all the documents in the chain of title of the '445 Patent, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

AstraZeneca AB also certifies that it is the successor of Astra Aktiebolag, which is the assignee of the entire right, title, and interest in U.S. Patent No. 5,830,853 (the '853 Patent), issued from USSN 08/582,702. An assignment to Astra Aktiebolag was recorded in the Patent and Trademark Office at Reel 7892, Frame 0168 on April 8, 1996.

The undersigned has reviewed all the documents in the chain of title of the '853 Patent, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

AstraZeneca AB also certifies that it is the successor of Astra Aktiebolag, which is the assignee of the entire right, title, and interest in U.S. Patent No. 6,004,574 (the '574 Patent), issued from USSN 08/617,753. An assignment to Astra Aktiebolag was recorded in the Patent and Trademark Office at Reel 8966, Frame 0574, on March 18, 1996.

The undersigned has reviewed all the documents in the chain of title of the '574 Patent, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

AstraZeneca AB also certifies that it is the successor of Astra Aktiebolag, which is the assignee of the entire right, title, and interest in U.S. Patent No. 6,165,976 (the '976 Patent), issued from USSN 09/072,717, by virtue of an assignment from the inventors thereof to Astra Aktiebolag in a predecessor application, USSN 08/583,205. That assignment to Astra Aktiebolag was recorded in the Patent and Trademark Office at Reel 8188, Frame 0576, on April 8, 1996.

The undersigned has reviewed all the documents in the chain of title of the '976 Patent, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

AstraZeneca AB also certifies that it is the successor of AB Astra, which is the assignee of the entire right, title, and interest in U.S. Patent No. 5,518,998 (the '998 Patent), issued from USSN 08/265,372, by virtue of an assignment thereof to AB Astra. The assignment was recorded in the Patent and Trademark Office at Reel 7231, Frame 0628 on September 6, 1994. The Certificate of Registration certifying the name change from Aktiebolaget Astra (i.e., AB Astra) to AstraZeneca AB was recorded at Reel 011111, Frame 0237 on September 19, 2000.

The undersigned has reviewed all the documents in the chain of title of the '998 Patent, and, to the best of undersigned's knowledge and belief, title is in AstraZeneca AB.

The undersigned is empowered to act on behalf of the assignee.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-captioned application subsequent to the expiration date of the '902 Patent. Further, any patent granted on the above-captioned application shall be enforceable only for and during such period that said patent is commonly owned with the '902 Patent.

AstraZeneca AB does not disclaim any terminal part of any patent granted on the above-captioned application prior to the expiration date of the full statutory term of the '902 Patent in the event that the '902 Patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-captioned application subsequent to the expiration date of the '445 Patent. Further, any patent granted on the above-captioned application shall be

enforceable only for and during such period that said patent is commonly owned with the '445 Patent.

AstraZeneca AB does not disclaim any terminal part of any patent granted on the above-captioned application prior to the expiration date of the full statutory term of the '445 Patent in the event that the '445 Patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-captioned application subsequent to the expiration date of the '853 Patent. Further, any patent granted on the above-captioned application shall be enforceable only for and during such period that said patent is commonly owned with the '853 Patent.

AstraZeneca AB does not disclaim any terminal part of any patent granted on the above-captioned application prior to the expiration date of the full statutory term of the '853 Patent in the event that the '853 Patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-captioned application subsequent to the expiration date of the '574 Patent. Further, any patent granted on the above-captioned application shall be

enforceable only for and during such period that said patent is commonly owned with the '574 Patent.

AstraZeneca AB does not disclaim any terminal part of any patent granted on the above-captioned application prior to the expiration date of the full statutory term of the '574 Patent in the event that the '574 Patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-captioned application subsequent to the expiration date of the '976 Patent. Further, any patent granted on the above-captioned application shall be enforceable only for and during such period that said patent is commonly owned with the '976 Patent.

AstraZeneca AB does not disclaim any terminal part of any patent granted on the above-captioned application prior to the expiration date of the full statutory term of the '976 Patent in the event that the '976 Patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.

This disclaimer runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

Pursuant to 37 CFR §1.321(b), and to obviate a double patenting rejection, AstraZeneca AB hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the above-captioned application subsequent to the expiration date of the '998 Patent. Further, any patent granted on the above-captioned application shall be

Applicant : Kjell G. E. Bäckström et al.  
Serial No. : 08/736,267  
Filed : October 24, 1996  
Page : 6

Attorney's Docket No.: 06275-004001 / D 1271-7 US

enforceable only for and during such period that said patent is commonly owned with the '998 Patent.

AstraZeneca AB does not disclaim any terminal part of any patent granted on the above-captioned application prior to the expiration date of the full statutory term of the '998 Patent in the event that the '998 Patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term, except for the separation of legal title as stated above.


This disclaimer runs with any patent granted on the above-captioned application and is binding upon the grantee, its successors or assigns.

A check for \$660 is enclosed. Please charge any additional fees, or make any credits, to Deposit Account No. 06-1050, referencing Attorney Docket No. 06275-004001.

Date:

March 17, 2003

Respectfully submitted,

  
Janis K. Fraser, Ph.D., M.D.  
Reg. No. 34,819

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

O I P E JC176  
MAR 24 2003  
PATENT & TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APRIL 10, 2001

PTAS



\*101602237A\*

FISH & RICHARDSON P.C.  
JANIS K. FRASER  
225 FRANKLIN STREET  
BOSTON, MA 02110-2804

UNITED STATES PATENT AND TRADEMARK OFFICE  
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/22/2001

REEL/FRAME: 011469/0958

NUMBER OF PAGES: 6

BRIEF: CERTIFICATE OF REGISTRATION

ASSIGNOR:  
AB ASTRA

DOC DATE: 01/13/2000

ASSIGNEE:  
ASTRAZENECA AB  
S-151 85 SODERTALJE, SWEDEN

SERIAL NUMBER: 08736267  
PATENT NUMBER:

FILING DATE: 10/24/1996  
ISSUE DATE:

RECEIVED  
MAR 28 2003

TECH CENTER 1600/2900

KIMBERLY WHITE, EXAMINER  
ASSIGNMENT DIVISION  
OFFICE OF PUBLIC RECORDS


RECEIVED

APR 17 2001

FISH & RICHARDSON, P.C.  
BOSTON OFFICE

02-01-2001

Docket No. 06275-004001



RECOR

101602237

PATENTS ONLY



Commissioner for Patents: Please record the attached original document(s) or copy(ies).

1. Name of conveying party(ies): AB Astra Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies): AstraZeneca AB S-151 85 Södertälje Sweden Additional names/addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance: Certificate of Registration Execution Date: January 13, 2000	
4. Application number(s) or patent number(s): If this document is being filed with a new application, the execution date of the application is: A. Patent Application No(s).: 08/736,267	B: Patent No(s).: Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
5. Name/address of party to whom correspondence concerning this document should be mailed: JANIS K. FRASER, Fish & Richardson P.C., 225 Franklin Street Boston, MA 02110-2804	RECEIVED JAN 22 2001 6. Total number of applications/patents involved: 1 7. Total fee (37 CFR §3.41): \$40 Enclosed Authorized to charge Deposit Account. 8. Deposit Account No.: 06-1050 Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050.
DO NOT USE THIS SPACE	
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>	
John T. Li Reg. No. 44,210 Name of Person Signing	Signature <i>John T. Li</i> Date <i>1-12-01</i>
Total number of pages including coversheet, attachments and document: 6	

20166770.doc

01/31/2001 DBYRNE 00000206 08736267

01 FC:581

40.00 0P

## CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner of Patents, Washington, D.C. 20231.

January 12, 2001  
Date of Deposit

Signature

Jeanine Mekhitarian  
Typed Name of Person Signing Certificate)

SWEDEN

Registration number: 556011-7482

Date of registration: 1913-10-31

Company name: AstraZeneca AB

Address:

Registered office: 151 85 SÖDERTÄLJE  
Södertälje

Share capital: SEK 0.054.029.453,50



BOARD OF DIRECTORS:

440802-3556 Björnsson, Björn Einar, (A), Bäckahästvägen 3,  
240 13 GENARP  
500523-4330 Lerenius, Per Göran, (E), Pettersbergsvägen 66,  
129 40 HÄGERSTEN  
430319 McKillop, Thomas Fulton Wilson, (E), (O), Flat 3,  
15 Stanhope Gate, LONDON W1Y 6LN, STORBRITANNIEN OCH NORDIRLAND  
590227 Symonds, Jonathan, (E), 16 Moor Lane, Rickmansworth,  
Hertfordshire, WD3 1SG, STORBRITANNIEN OCH NORDIRLAND  
591026-0024 Sörensen, Pia Carina, (A), Skämbylötsvägen 6,  
540 60 JÄRNLÄSTYCKEBRUK  
560902-0093 Wallenberg, Marcus, Vidbynäs Gård 33, 146 91 ÖSMO  
390324-5714 Wilhelmsson, Claes-Erik, Strandvägen 63,  
115 23 STOCKHOLM

DEPUTY MEMBERS OF THE BOARD:

690810-6690 Johansson, Stig-Ove Michael, Ekhöjden Taxinge-Näsby,  
155 93 NYKVARN  
580928-3335 Lundblad, Karl Alf Lennart, Envigsgränden 1,  
224 75 LUND

MANAGING DIRECTOR:

420527-5938 From, Per Anders Gideon, Drottningholmsvägen 1 6tr.,  
112 42 STOCKHOLM

OTHER PERSONS AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY:

520121-1751 Johansson, John Roland, Pilvägen 8, 610 60 TYSTBERGA  
561115-2710 Johansson, Per Olof Kjell, Bränningstrandsvägen 72,  
151 39 SÖDERTÄLJE  
580712-5116 Linde, Carl Fredrik Johannes, Auravägen 24,  
182 68 DJURSHOLM  
580111-2086 Ljungqvist, Margit Inga Susanne, Solhemsvägen 13A,  
141 31 HUDDINGE

CONTD.

SWEDEN

Registration number: 556011-7482

Date of registration: 1913-10-31

Company name: AstraZeneca AB

Address:

Registered office: 151 85 SÖDERTÄLJE  
Södertälje

Share capital: SEK 2.054.029.452,50

470520-1939 Sveréus, Björn Gustaf, Hedåvägen 9, 152 51 SÖDERTÄLJE

COMPANY AUDITORS:

430319-0658 Magnusson, Bo Vilhelm, Karpvägen 36, 181 30 LIDINGÖ

COMPANY AUDITOR:

556479-9103 Deloitte & Touche Stockholm Aktiebolag  
Box 101 52, 121 26 STOCKHOLM-GLOÖEN

Principally responsible auditor: 430319-0658 Magnusson, Bo Vilhelm  
Karpvägen 36, 181 30 LIDINGÖ

SIGNATORY POWER:

In addition to the Board of the Directors,

Lerénus, Per Göran  
McKillop, Thomas Fulton Wilson  
From, Per Anders Gideon  
Linde, Carl Fredrik Johánnes

individually,

or any two jointly of

Wilhelsson, Claes-Erik  
Johansson, John Roland  
Johansson, Per Olof Kjell  
Ljungqvist, Margit Inga Susanne  
Sveréus, Björn Gustaf

are entitled to sign on behalf of the company.

SECONDARY NAMES:

Astra

FINANCIAL YEAR:

Registered financial year: 0101-1231

Latest annual report submitted covers financial  
period 980101-981231

CONT'D.

SWEDEN

Registration number: 556011-7482

Date of registration: 1913-10-31

Company name: AstraZeneca AB

Address:

Registered office: 151 85 SÖDERTÄLJE  
Södertälje

Share capital: SEK 2.054.029.452,50

DATE OF REGISTRATION OF CURRENT AND PREVIOUS COMPANY NAMES:

2000-01-03 AstraZeneca AB

1994-06-20 Astra Aktiebolag

1966-05-12 Aktiebolaget Astra

1913-10-31 Aktiebolaget Astra, Apotekarnas Kemiska Fabriker

SUNDSVALL 2000-01-13

Ex officio

  
MALIN SELLÉN



- (A) = employee representative
- (U) = person resident outside EEA
- (E) = person resident outside Sweden but within EEA
- (O) = chairman of the board


I, JOHN BICKMORE HODGSON of Wilmslow Cheshire  
England Notary Public duly authorised admitted and sworn and  
practising within the United Kingdom of Great Britain and  
Northern Ireland do hereby certify that the photostat matter  
hereto annexed and on which I have impressed my notarial seal is  
a true copy of a document the original of which was produced to  
me at *Wilmslow Cheshire England*

.....  
this 15<sup>th</sup> day of August

2000

*John Bickmore Hodgson*  
John Bickmore Hodgson  
Notary Public

Certificate



The enclosed Certificate of Registration has been issued for

AstraZeneca AB  
registration number: 556011-7482

which is registered as "PUBLIKT", generally written (publ), in the Companies Register kept by this office, the Companies Department of the Patent and Registration Office, Sweden.

A Swedish company classed as "PUBLIKT" is entitled to invite the general public to subscribe for or acquire shares and other securities which the company issues.

The share capital for a company classed as "PUBLIKT" must amount to a minimum of SEK 500 000.

Sundsvall, 13<sup>th</sup> January, 2000

*[Signature]* *Print*  
True copy certified by:

Bolagsavdelningen

851 81 Sundsvall

Besöksadress  
Badhusparken

Postgiro 95 06 08 - 0  
Bankgiro 5050 - 0255

Telefon 060 - 18 40 00  
Telefax 060 - 12 64 77